Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis

Folia Histochemica et Cytobiologica

Volumn 46, Issue 4, 2008, Pages 437-442

  Sulik, Artur ^a   Chyczewski, Lech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Immunohistochemistry; Matrix metalloproteinases; Meningitis; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; ASTROCYTE; AUTOPSY; BACTERIAL MENINGITIS; BRAIN TISSUE; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY INFILTRATE; MALE; MENINX; MONONUCLEAR CELL; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; VIRUS MENINGITIS; ENZYMOLOGY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; STAINING; VIROLOGY;

BACTERIA (MICROORGANISMS);

ADULT; AGED; ASTROCYTES; CENTRAL NERVOUS SYSTEM; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MENINGES; MENINGITIS, BACTERIAL; MENINGITIS, VIRAL; MIDDLE AGED; STAINING AND LABELING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 60549114340     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0058-8     Document Type: Article

References (22)

1. Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003;136:46-53.
2. Nygardas PT, Hinkkanen AE. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2002;128:245-54.
3. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003;43:191-196.
4. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37:1399-1406.
5. Lee KY, Kim EH, Yang WS, et al. Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis. J Neurol Sci. 2004;220:73-78.
6. Sellner J, Leib SL. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis. 2006;21:647-656.
7. Lindberg RL, Sorsa T, Tervahartiala T, et al. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol. 2006;32:304-317.
8. Yushchenko M, Weber F, Mäder M, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol. 2000;110:244-251.
9. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005;6:931-944.
10. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99-113.
11. Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y, Osame M. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sci. 2000;173:45-52.
12. Shapiro S, Miller A, Lahat N, Sobel E, Lerner A. Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. J Neurol Sci. 2003;206:43-48.
13. Kolb SA, Lahrtz F, Paul R, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol. 1998;84:143-150.
14. Michel U, Zobotke R, Mäder M, Nau R. Regulation of matrix metalloproteinase expression in endothelial cells by heat-inactivated Streptococcus pneumoniae. Infect Immun. 2001;69:1914-1916.
15. Giraudon P, Szymocha R, Buart S, et al. T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. J Immunol. 2000;164:2718-2727.
16. Gardner J, Borgmann K, Deshpande MS, et al. Potential mechanisms for astrocyte-TIMP-1 downregulation in chronic inflammatory diseases. J Neurosci Res. 2006;83:1281-1292.
17. Gardner J, Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res. 2003;74:801-806.
18. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
19. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2008 doi:10.1016/j.neuroscience.2008.06.025
20. Chen KM, Lee HH, Chou HL, Liu JY, Tsai BC, Lai SC. Upregulation of MMP-9/ TIMP-1 enzymatic system in eosinophilic meningitis caused by Angiostrongylus cantonensis. Int J Exp Pathol. 2005;86:81-89.
21. Campbell SJ, Finlay M, Clements JM, Wells G, Miller KM, Perry VH, Anthony DC. Reduction of excitotoxicity and associated leukocyte recruitment by a broad-spectrum matrix metalloproteinase inhibitor. J Neurochem. 2004;89:1378-1386.
22. Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005;128:1622-1633.